PriceTargets.com logo

Harrow - HROW Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.67
  • Forecasted Upside: 43.90%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$39.38 As of 12/3/2024 12:51 PM ET
▼ -2.48 (-5.92%)

This chart shows the closing price for HROW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harrow Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HROW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HROW

Analyst Price Target is $56.67
▲ +43.90% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Harrow in the last 3 months. The average price target is $56.67, with a high forecast of $65.00 and a low forecast of $50.00. The average price target represents a 43.90% upside from the last price of $39.38.

This chart shows the closing price for HROW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Harrow. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/4/2024Lake Street CapitalBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
10/4/2024Craig HallumBoost TargetBuy ➝ Buy$45.00 ➝ $65.00
8/29/2024B. RileyReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/9/2024Craig HallumBoost TargetBuy ➝ Buy$30.00 ➝ $45.00
8/9/2024B. RileyBoost TargetBuy ➝ Buy$29.00 ➝ $50.00
6/21/2024Craig HallumBoost TargetBuy ➝ Buy$26.00 ➝ $30.00
6/3/2024Lake Street CapitalBoost TargetBuy ➝ Buy$20.00 ➝ $25.00
5/15/2024Craig HallumBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
5/15/2024B. RileyReiterated RatingBuy ➝ Buy$26.00 ➝ $29.00
4/11/2024Craig HallumInitiated CoverageBuy$24.00
3/22/2024B. RileyLower TargetBuy ➝ Buy$30.00 ➝ $26.00
8/10/2023LADENBURG THALM/SH SHBoost Target$33.70 ➝ $34.40
7/20/2023B. RileyBoost TargetBuy$42.00 ➝ $45.00
5/12/2023LADENBURG THALM/SH SHBoost Target$27.20 ➝ $32.40
5/4/2023B. RileyReiterated RatingBuy
4/17/2023Lake Street CapitalBoost TargetBuy$24.00 ➝ $37.00
1/24/2023Lake Street CapitalBoost Target$17.00 ➝ $24.00
1/5/2023B. RileyBoost Target$17.00 ➝ $22.00
9/8/2022B. RileyInitiated CoverageBuy$17.00
5/20/2022B. RileyBoost TargetBuy$17.00 ➝ $20.00
10/14/2021B. RileyInitiated CoverageBuy$16.00
9/23/2021AegisInitiated CoverageBuy$15.00
7/2/2021LADENBURG THALM/SH SHInitiated CoverageBuy$14.25
5/12/2021B. RileyBoost TargetBuy$14.00 ➝ $15.00
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$12.00 ➝ $14.00
4/7/2020B. RileyLower TargetBuy$12.00 ➝ $10.00
3/16/2020B. RileyLower TargetBuy$12.75 ➝ $12.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 10 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/6/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 3 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 17 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 17 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Harrow logo
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $39.38
Low: $39.20
High: $42.01

50 Day Range

MA: $47.56
Low: $37.97
High: $57.48

52 Week Range

Now: $39.38
Low: $9.13
High: $59.23

Volume

134,739 shs

Average Volume

508,854 shs

Market Capitalization

$1.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Harrow?

The following Wall Street analysts have issued reports on Harrow in the last twelve months: B. Riley, Craig Hallum, Lake Street Capital, and TheStreet.
View the latest analyst ratings for HROW.

What is the current price target for Harrow?

0 Wall Street analysts have set twelve-month price targets for Harrow in the last year. Their average twelve-month price target is $56.67, suggesting a possible upside of 43.9%. Craig Hallum has the highest price target set, predicting HROW will reach $65.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $50.00 for Harrow in the next year.
View the latest price targets for HROW.

What is the current consensus analyst rating for Harrow?

Harrow currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HROW will outperform the market and that investors should add to their positions of Harrow.
View the latest ratings for HROW.

What other companies compete with Harrow?

Other companies that are similar to Harrow include Viking Therapeutics, Ionis Pharmaceuticals, TG Therapeutics, Crinetics Pharmaceuticals and BridgeBio Pharma. Learn More about companies similar to Harrow.

How do I contact Harrow's investor relations team?

Harrow's physical mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company's listed phone number is (615) 733-4730 and its investor relations email address is [email protected]. The official website for Harrow is www.harrowinc.com. Learn More about contacing Harrow investor relations.